Carbogen Amcis CEO: Competition in ADC sector not a concern

Competition not a concern says Carbogen Amcis CEO

Investing in antibody-drug conjugates (ADCs) made sense despite CMO competition and the fact few of these hybrid drugs have been approved to date says Carbogen Amcis CEO, Mark Griffiths.

Carbogen Amcis – which is part of Indian drugmaker  Dishman - unveiled that it had invested in dedicated cleanroom and ADC manufacturing capacity at two facilities earlier this week, just weeks after teaming up with St Asaph, Wales-based specialist ADC Biotechnology.

Carbogen is not the only contractor to view these biopharmaceutical-small molecule hybrids as a growth opportunity, Lonza, Piramal and Novasep have all recently added capacity. However the increasingly competitive nature of the ADC services sector is not a concern for Carbogen according to CEO Mark Griffiths.   

We see a competitive environment not as a deterrent, but as a stimulant to our business,” he told BioPharma-Reporter.com, adding that Carbogen’s track record working with high-potency active pharmaceutical ingredients (APIs) combined with the new investment “gives us a strong competitive advantage.”

Griffiths also cited the drug industry’s focus on targeted therapies as a driver for the investment, particularly the increasing number of opportunities in the field of cancer treatment development.

Over the past several years we have collaborated with a growing number of customers who operate in the ADC space. With the recent advances in highly-targeted cancer therapies, we see a lot of growth in demand for ADCs among our customers and we decided to invest in enhancing our capabilities to be better equipped to support our customers‘ ADCs projects.”

Regulatory approvals

But is it really wise to invest in ADCs? The ability to deliver high potency APIs in a more targeted manner is clearly an important advance, but as yet very few of this type of hybrid medication have gained regulatory approval.

While reports suggest that as many as 60 ADCs are in development to date only Takeda’s Adcetris – which is cleared in Europe and the US – Roche’s Kadcyla – OKed in the US and under review in Europe – and Pfizer’s Mylotarg – never passed by the EMA and withdrawn in the US – have been approved.

However, Carbogen still expects drug industry demand for ADC services to grow according to Griffiths, who said: “This is the paradigm of our industry. You always have a lot of candidates and only few successful ones, which reach the market in the end.

This is exactly why our investment makes sense,” he continued, saying that the firm’s focus will be on enabling customers to move their clinical projects forward without taking the risk of a major CAPEX investment.

We never compete with our customers, but do our best to support and exceed their business expectations, thereby facilitating their success rate."

Related News

Roche to build $208m ADC plant

Roche to build $208m ADC plant to support Kadcyla production

More investment in ADCs - 'warhead' cytotoxic small molecule linked to cancer-targeting mAb

MedImmune looks to 'next generation biologics' with $200m ADC investment

Another day, another ADC investment: SAFC adds ADC capacity

Another day, another ADC investment: SAFC adds commercial-scale capacity

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

MacroGenics extends license of Polytherics' Thiobridge ADC tech

MacroGenics extends license of Polytherics' Thiobridge ADC tech

Carbogen Amcis has signed a long-term lease for an ADC unit in Vionnaz, Switzerland

Carbogen Amcis takes over Swiss plant to boost ADC offering

Novasep expanding conjugation capability to simplify ADC supply chain

Novasep expanding conjugation capability to help simplify ADC supply chain

Carbogen Amcis to buy GEA plant in Bubendorf (source Google)

Carbogen Amcis to buy GEA plant and convert it for API production

Carbogen Amcis invests in ADC capacity

Carbogen Amcis invests in ADC capacity

ADC Bio Expands Lab Services in Response to Demand

ADC Bio Expands Lab Services in Response to Demand

Lonza to double ADC capacity

Lonza to double ADC capacity to address Visp challenge

Synthon Unveils ADC Facility as Data Show Promise for First Candidate

Wuxi to Help Develop, Manufacture ADC Candidate in China

Wuxi to Help Develop, Manufacture ADC Candidate in China

Catalent enters ADC market

Catalent Gets ADC Tech and Enters Fast-Growing Niche Market

Goodwin

Demand Across Biopharma Drives Goodwin and Coldstream ADC Partnership

ADC invests in production tech

ADC Bio open to antibody drug conjugate collaborations and CMO takovers

Eli Lilly could pay Immunogen up to $200m for use of its ADC tech

Eli Lilly Licenses $200m ADC Tech from Immunogen

Piramal Invests $2.5m to Expand ADC Capacity in Scotland

Piramal Invests $2.5m to Expand ADC Capacity in Scotland

Baxter ups its cytotoxicity capability

Baxter Expands its Cytotoxicity Capabilities - Again

Lonza ramps up complex manufacturing at Visp

Lonza to boost complex manufacturing at underperforming Visp plant

Related Products

See more related products